Three IPOs and two SPACs priced this week, and two SPACs submitted filings. City Therapeutics (CTY) priced its upsized IPO at the midpoint to raise $200 million at a $1.0 billion market cap. City Therapeutics is a Phase 1 biotech developing RNA interference...read more
Frazier Life Sciences Acquisition II, the second blank check company formed by Frazier targeting biotech, raised $75 million by offering 7.5 million shares at $10. Unlike most SPACs, it did not offer units with warrants or rights attached. Frazier Life...read more
One IPO and two SPACs debuted this week, although more deals were originally on the calendar. Five IPOs and three SPACs submitted initial filings. The biggest story in the IPO market this week may be the deals that didn’t get done. Homeowners insurance...read more
Frazier Life Sciences Acquisition II, the second blank check company formed by Frazier targeting biotech, filed on Thursday with the SEC to raise up to $75 million in an initial public offering. The company plans to raise $75 million by offering 7.5 million...read more
US IPO Weekly Recap: Biotechs City Therapeutics and Iambic headline the week’s pricings
Three IPOs and two SPACs priced this week, and two SPACs submitted filings. City Therapeutics (CTY) priced its upsized IPO at the midpoint to raise $200 million at a $1.0 billion market cap. City Therapeutics is a Phase 1 biotech developing RNA interference...read more
Biotech-focused SPAC Frazier Life Sciences Acquisition II prices $75 million IPO
Frazier Life Sciences Acquisition II, the second blank check company formed by Frazier targeting biotech, raised $75 million by offering 7.5 million shares at $10. Unlike most SPACs, it did not offer units with warrants or rights attached. Frazier Life...read more
US IPO Weekly Recap: Postponed deals put damper on fall IPO market
One IPO and two SPACs debuted this week, although more deals were originally on the calendar. Five IPOs and three SPACs submitted initial filings. The biggest story in the IPO market this week may be the deals that didn’t get done. Homeowners insurance...read more
Biotech SPAC Frazier Life Sciences Acquisition II files for a $75 million IPO
Frazier Life Sciences Acquisition II, the second blank check company formed by Frazier targeting biotech, filed on Thursday with the SEC to raise up to $75 million in an initial public offering. The company plans to raise $75 million by offering 7.5 million...read more